Prysmian S.p.A. (PRYMF)
| Previous Close | 0.00 |
| Open | 72.71 |
| Bid | 65.40 x 41800 |
| Ask | 71.10 x 39400 |
| Day's Range | 69.40 - 72.71 |
| 52 Week Range | 33.85 - 72.71 |
| Volume | |
| Avg. Volume | 598 |
| Market Cap | 19.786B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | 33.89 |
| EPS (TTM) | 1.93 |
| Earnings Date | Aug 01, 2024 |
| Forward Dividend & Yield | 0.75 (1.15%) |
| Ex-Dividend Date | Apr 22, 2024 |
| 1y Target Est | N/A |
- Reuters
Prysmian shares ease from recent high as H1 results show 'some weakness'
MILAN (Reuters) -Prysmian has seen "some weakness" in its first-half performance, the world's No.1 cable maker said on Thursday, as margin pressure in its key electrification business took the shine off results for the period. Based on 2023 sales data, the deal increased Prysmian's size by more than 15%. Shares in the company, which by 1010 GMT were down 4.5%, have gained over 50% since the start of the year, hitting a record 64.66 euros on July 24 supported by Prysmian's expected role in global long-term trends of energy transition and digitalisation.
Simply Wall St.Exploring Three Top Value Stocks With Intrinsic Discounts Ranging From 12.3% To 36.7%
As global markets exhibit mixed performances with a notable pivot towards value and small-cap stocks, investors are keenly observing shifts caused by geopolitical tensions and economic policies. In this context, identifying stocks that appear undervalued relative to their intrinsic value could be particularly compelling, offering potential opportunities for discerning investors in the current market environment.
PR NewswireProtagonist Therapeutics Set to Join S&P SmallCap 600
Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions.
